Navigation Links
Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
Date:9/19/2013

MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- Protagonist Therapeutics today announced the addition of $4 million to its previously announced Series B private financing, bringing the total raised in this round to $18 million. Pharmstandard International S.A., a holding company of the major pharmaceutical company in Russia, OJSC Pharmstandard (LSE: PHST), has joined the round as a new investor.

(Logo: http://photos.prnewswire.com/prnh/20130501/MM06086LOGO)

"Protagonist's orally stable peptides represent a game-changing approach that especially enables the development of orally administered NCEs (new chemical entities) for inflammatory bowel diseases and other gastro-intestinal disorders," said Alexander Shuster, Ph.D., President of Inbio Ventures, a management company representing Pharmstandard International. "We were impressed by the company's technology, partnerships, development achievements to date, and the management team."

"The addition of Pharmstandard to our investor base reflects the growing international interest in the field of orally active peptides, as well as recognition by investors of the significant advantages offered by our technology over other approaches," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. "This additional international investment enables us to further focus efforts on building a strong pipeline of developmental candidates for our internal pipeline and selective asset-based partnering."

About Pharmstandard International S.A./Inbio Ventures

Pharmstandard International S.A. – a holding company fully committed by OJSC Pharmstandard (LSE:PHST) – is a venture investments fund focuse
'/>"/>

SOURCE Protagonist Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
2. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
3. Adheron Therapeutics Names New Senior Leadership
4. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
5. Echo Therapeutics Sends Response to Shareholder Letter
6. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
7. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
8. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
9. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
10. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
11. Oncology Therapeutics Market in India to 2018 Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 A new report by  ... will reach $22.4bn in 2019. That revenue forecast and ... Market Prospects 2015-2025 ,  published in March ... to provide forecasts and qualitative analyses of the antithrombotic ... consultancy in London, UK . It ...
(Date:5/1/2015)... According to a new ... Consumables), by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), ... - Analysis & Global Forecast to 2019", published ... Production Market for the forecast period of 2014 ... $2.572 Billion by 2019 from $1.425 Billion in ...
(Date:4/30/2015)... 30, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, announced ... quarter of 2015 on May 7, 2015 after the ... will also host a conference call at 4:30 p.m. ... first quarter financial results. During the conference call, material ...
(Date:4/30/2015)... MINNEAPOLIS, MN , April 30, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has commenced ... addition, BioAmber expects to grant the underwriters a 30-day ... of the shares of common stock offered in the ... and there can be no assurance as to whether ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Entrepreneur Anthony ... Directors, IRVINE, Calif., Sept. 5 NeoMatrix, developer of ... to,identify breast cancer risk, announced today that the company has ... enable an expanded,market release of the HALO System, which is ...
... Sept. 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... the Bear Stearns 20th Annual Healthcare Conference on September,11, ... Time) at the Grand,Hyatt Hotel in New York City. ... to provide a corporate overview of the,company and its ...
... the Key Problems Faced by Insomniacs, i.e.,Sleep Onset and ... Today at 11:00 am CET (10:00 am UK,time, 5:00 ... Congress in,Australia HAMBURG, Germany and OXFORD, England, September ... the worldsleep07 congress in Cairns, Australia the,details of the ...
Cached Biology Technology:NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 2NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 3NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 4Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 2Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 4
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/26/2015)... 26, 2015 The Granite Club, ... and athletic club, today announced it has implemented a ... of movement for members and staff, while restricting access ... process, we selected FST,s IMID Access system because it ... our members and staff, in addition to unparalleled security," ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch ... of MDC and Charit in Berlin-Buch have gained ... and their molecular repertoire. Dr. Max Werth, Katharina ... transcription factor (grainyhead-like 2, Grhl2), which regulates the ...
... PhD student are part of a research team that ... oxygen levels in the oceans high enough to establish ... By examining ancient-ocean sediments, Kurt Konhauser, student ... last glacier to encircle Earth receded, leaving behind glacial ...
... DURHAM, N.H. A major new study that sounds ... the world,s seagrass species are faring somewhat better, says a ... the study. Fred Short, UNH research professor ... was among the 174 scientists who contributed to "The Impact ...
Cached Biology News:New insights into the development of epithelial cells 2UNH's Fred Short adds seagrass data to major conservation study 2